N
Description
Nanoform is a publicly traded Finnish company (Nasdaq First North) specializing in pharmaceutical nanotechnology. Its patented CESS® technology produces API nanoparticles as small as 10 nm, improving bioavailability and enabling new delivery routes. Lead product: Nanoenzalutamide for prostate cancer, launch 2027-2028.